Century Therapeutics, Inc.
IPSC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001850119
In the last 90 days, Century Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 100 institutions reported holding it in 13F filings for Q2 2026, worth $387.0M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Century Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 2 insiders, $10.4K in total
- Insiders trading
- 2
- Net value
- −$10.4K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Century Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Russotti Gregory | See Remarks | 509,198 | Sep 15, 2026 | 8 |
| Carr Douglas | SVP Finance & Operations | 502,907 | Sep 15, 2026 | 12 |
| Pfeiffenberger Brent | President and CEO | 3,633,839 | Sep 15, 2026 | 14 |
| Truitt Joseph | Director | – | Sep 10, 2026 | 1 |
| Cowan Chad | Chief Scientific Officer | 1,175,322 | Jun 15, 2026 | 7 |
| Quimi Daphne | Director | 5,000 | Jun 12, 2026 | 1 |
| Blackwell Kimberly | Director | – | Jun 12, 2026 | 1 |
| Riva Alessandro | Director | – | Jun 12, 2026 | 1 |
| Lee Han Myung | Director | – | Jun 12, 2026 | 2 |
| Murphy Martin Patrick | Director | – | Jun 12, 2026 | 2 |
| Jimenez Joseph | Director | – | Jun 16, 2025 | 0 |
| Butitta Cynthia M | Director | – | Jun 16, 2025 | 0 |
| Walbert Timothy P | Director | – | Jun 16, 2025 | 0 |
| Carlo Rizzuto | Director | – | Jun 16, 2025 | 0 |
| Farid Adrienne | Chief Operations Officer | 250,141 | Jun 11, 2025 | 0 |
| Conn Morgan | Chief Finanical Officer | 79,648 | Mar 12, 2025 | 0 |
| Levitsky Hyam | President of R&D | 24,000 | Mar 11, 2024 | 0 |
| Diem Michael Craig | Chief Financial Officer | 253,533 | Nov 3, 2023 | 0 |
| Borges Luis | Chief Scientific Officer | 256,535 | Apr 5, 2023 | 0 |
| Flores Osvaldo | Chief Executive Officer | – | Feb 6, 2023 | 0 |
| Versant Venture Capital VI, L.P. | 10% Owner | 11,452,014 | Aug 11, 2022 | 0 |
| Versant Ventures VI GP-GP, LLC | 10% Owner | 11,452,014 | Aug 11, 2022 | 0 |
| Versant Ventures VI GP, L.P. | 10% Owner | 11,452,014 | Aug 11, 2022 | 0 |
| Versant Vantage II, L.P. | 10% Owner | 11,452,014 | Aug 11, 2022 | 0 |
| Versant Vantage II GP-GP, LLC | 10% Owner | 11,452,014 | Aug 11, 2022 | 0 |
| Versant Vantage II GP, L.P. | 10% Owner | 11,452,014 | Aug 11, 2022 | 0 |
| Casdin Eli | Director | – | Jun 10, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 (view filing) | Mar 12 | 4 days | Russotti GregorySee Remarks | SSale | −10.1K | $2.55 | −$25.7K | −1.9%515.4K after | |
| May 6, 2026 (view filing) | May 4 | 2 days | Carr DouglasSVP Finance & Operations | SSale | −264 | $2.34 | −$617.76 | −0.1%507.0K after | |
| Jun 9, 2026 (view filing) | Jun 8 | 1 day | Carr DouglasSVP Finance & Operations | SSale | −249 | $2.11 | −$525.39 | 0.0%506.7K after | |
| Jun 9, 2026 (view filing) | Jun 8 | 1 day | Russotti GregorySee Remarks | SSale | −524 | $2.11 | −$1.11K | −0.1%514.9K after | |
| Jun 15, 2026 (view filing) | Jun 12 | 3 days | Carr DouglasSVP Finance & Operations | SSale | −1.65K | $2.23 | −$3.69K | −0.3%505.1K after | |
| Jun 15, 2026 (view filing) | Jun 12 | 3 days | Russotti GregorySee Remarks | SSale | −2.58K | $2.23 | −$5.76K | −0.5%512.3K after | |
| Aug 5, 2026 (view filing)4:08 PM ET | Aug 3 | 2 days | Carr DouglasSVP Finance & Operations | SSale | −275 | $1.98 | −$543.68 | −0.1%504.8K after | |
| Sep 9, 2026 (view filing)4:34 PM ET | Sep 8 | 1 day | Carr DouglasSVP Finance & Operations | SSale | −254 | $2.05 | −$520.7 | −0.1%504.6K after | |
| Sep 9, 2026 (view filing)4:35 PM ET | Sep 8 | 1 day | Russotti GregorySee Remarks | SSale | −534 | $2.05 | −$1.09K | −0.1%511.8K after | |
| Sep 15, 2026 (view filing)6:25 PM ET | Sep 14 | 1 day | Carr DouglasSVP Finance & Operations | SSale | −1.66K | $1.93 | −$3.20K | −0.3%502.9K after | |
| Sep 15, 2026 (view filing)6:25 PM ET | Sep 14 | 1 day | Russotti GregorySee Remarks | SSale | −2.59K | $1.93 | −$4.99K | −0.5%509.2K after |